Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 11, 2018
Update of the S1 guidelines on the definition and treatment of primary hyperhidrosisBerthold Rzany, Falk G Bechara, Konstantin Feise, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 8, 2013
Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar linesDoris Hexsel, Cristiano Brum, Carolina Siega, et al.
Aesthetic Surgery Journal|February 16, 2017
Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled TrialBenjamin Ascher, Philippe Kestemont, Dominique Boineau, et al.
Aesthetic Surgery Journal|September 25, 2019
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical TrialBenjamin Ascher, Berthold Rzany, Philippe Kestemont, et al.
Aesthetic Surgery Journal|March 21, 2019
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar LinesBenjamin Ascher, Berthold Rzany, Philippe Kestemont, et al.
Aesthetic Surgery Journal|August 3, 2022
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study DataNowell Solish, Benjamin Ascher, Rui L Avelar, et al.
Aesthetic Surgery Journal|April 6, 2019
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult PatientsBerthold-Josef Rzany, Benjamin Ascher, Rui L Avelar, et al.
The Lancet. Infectious Diseases|December 24, 2016
Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trialMichael Schwameis, Thomas Kündig, Gustave Huber, et al.
Pageof 2